{"data":{"id":"us/38-cfr-17.1220","jurisdiction":"us","citation":"38 CFR 17.1220","heading":"Provision of emergent suicide care.","body":"(a) Emergent suicide care will be provided to individuals eligible under § 17.1210 only if it is determined by a health care provider to be clinically necessary and in accord with generally accepted standards of medical practice.\n(b) Prescription drugs, biologicals, and medical devices that may be provided during a period of emergent suicide care under § 17.1215 must be approved by the Food and Drug Administration, unless the treating VA facility or non-VA facility is conducting formal clinical trials under an Investigational Device Exemption or an Investigational New Drug application, or the drugs, biologicals, or medical devices are prescribed under a compassionate use exemption.","path":["Title 38—Pensions, Bonuses, and Veterans' Relief","CHAPTER I—DEPARTMENT OF VETERANS AFFAIRS","PART 17—MEDICAL"],"source_url":"https://www.ecfr.gov/api/versioner/v1/full/2026-08-25/title-38.xml","current_through":"2026-08-25","vintage":"","retrieved_at":"2026-08-27T02:25:50Z","sha256":"268de1614706ef91e1a86fe8d3ac0dc8f5c5aedc817c6e1e42016a368ce7d047","source_id":"us-cfr","stale":true,"prev":"us/38-cfr-17.1215","next":"us/38-cfr-17.1225"},"notice":"GroundRules: Original legal text. Not legal advice."}